以全血细胞减少为首发表现的脾边缘区淋巴瘤1例报告

何涛; 王安康; 蒋禹; 李秋; 付文广

doi:10.3969/j.issn.1001-5256.2020.01.040

以全血细胞减少为首发表现的脾边缘区淋巴瘤1例报告

DOI: 10.3969/j.issn.1001-5256.2020.01.040

1. 西南医科大学附属医院肝胆外科
2. 西南医科大学附属医院四川省院士(专家)工作站

基金项目:

四川省科技计划项目基金(2018JY0283,2017SZYZF0015)；

详细信息

中图分类号: R733.1
计量
- 文章访问数: 1040
- HTML全文浏览量: 16
- PDF下载量: 225
- 被引次数: 0
出版历程
- 出版日期: 2020-01-20

Splenic marginal zone lymphoma with pancytopenia as the first presentation: A case report

Department of Hepatobiliary Surgery,The Affiliated Hospital of Southwest Medical University

Research funding:

摘要

摘要: <正>脾边缘区淋巴瘤(splenic marginal zone lymphoma,SMZL)是指原发于脾脏的B淋巴细胞性非霍奇金淋巴瘤。SMZL的发病率低,国内以全血细胞减少为首发表现的SMZL报道较少。为提高临床医务人员对SMZL的认识,现将本院诊治的1例报道如下。1病例资料患者女性,76岁,以"腹胀、纳差1年,全血细胞减少3 d"为主诉于2016年6月23日于本院就诊。1年前曾于本院就诊,患者无明显诱因出现腹胀,伴有纳差,无腹痛、腹泻,无畏寒发
- 淋巴瘤,B细胞,边缘区 /
- 脾 /
- 脾切除术 /
- 全血细胞减少
- lymphoma,B-cell,marginal zone /
- the spleen /
- splenectomy /
- pancytopenia

HTML全文

参考文献(21)

[1] ARCAINI L,BESSON C,FRIGENI M,et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection[J]. Blood,2016,128(21):2527-2532.

[2] FENSKE TS,HAMADANI M,COHEN JB,et al. Allogeneic hematopoietic cell transplantation as curative therapy for patients with non-Hodgkin lymphoma:Increasingly successful application to older patients[J]. Biol Blood Marrow Transplant,2016,22(9):1543-1551.

[3] GROTH CL,NEVEL KS,GWATHMEY KG,et al. Splenic marginal zone lymphoma:An indolent malignancy leading to the development of neurolymphomatosis[J]. Muscle Nerve,2017,55(3):440-444.

[4] YI S,YAN Y,XIONG W,et al. Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region[J]. Oncotarget,2017,8(58):98757-98770.

[5] SAADOUN D,SUAREZ F,LEFRERE F,et al. Splenic lymphoma with villous lymphocytes,associated with type II cryoglobulinemia and HCV infection:A new entity?[J]. Blood,2005,105(1):74-76.

[6] MATUTES E,OSCIER D,MONTALBAN C,et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic,staging and therapeutic criteria[J]. Leukemia,2008,22(3):487-495.

[7] KALPADAKIS C,PANGALIS GA,SACHANAS S,et al. No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab[J]. Leuk Lymphoma,2016,57(11):2705-2708.

[8] ARCAINI L,LAZZARINO M,COLOMBO N,et al. Splenic marginal zone lymphoma:Aprognostic model for clinical use[J].Bood,2006,107(12):4643-4649.

[9] CHACN JI,MOLLEJO M,MUOZ E,et al. Splenic marginal zone lymphoma:Clinical characteristics and prognostic factors in a series of 60 patients[J]. Blood,2002,100(5):1648-1654.

[10] YAN YT,YI SH,QIU LG. Advances in molecular genetics pathogenesis of splenic marginal zone lymphoma[J]. Chin J Hematol,2016,37(4):348-352.(in Chinese)阎禹廷，易树华，邱录贵．脾边缘区淋巴瘤发病机制研究进展[J]．中华血液学杂志，2016,37(4):348-352.

[11] HU Y,CHEN Y,WANG LH,et al. Identification of splenic marginal zone lymphoma from B lymphoproliferative disorders by flow cytometry[J]. J Exp Hematol,2014,22(2):349-356.(in Chinese)胡旸，陈艳，王丽华，等．用流式细胞术从B淋巴增殖性疾病中鉴别脾边缘带淋巴瘤[J]．中国实验血液学杂志，2014,22(2):349-356.

[12] BU F,FENG Q,WANG WY,et al. Splenic marginal zone lymphoma:A case report[J/CD]. Chin Arch General Surg(Electronic Version),2017,11(6):426-427.(in Chinese)卜凡，冯强，王文洋，等．脾边缘区B细胞淋巴瘤一例[J/CD]．中华普通外科学文献(电子版)，2017,11(6):426-427.

[13] KALPADAKIS C,PANGALIS GA,VASSILAKOPOULOS TP,et al. Treatment of splenic marginal zone lymphoma:Should splenectomy be abandoned?[J]. Leuk Lymphoma,2014,55(7):1463-1470.

[14] SALIDO M,BARC,OSCIER D,et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas:A multicenter study of the Splenic B-Cell Lymphoma Group[J]. Blood,2010,116(9):1479-1488.

[15] ARCAINI L,VARETTONI M,BOVERI E,et al. Distinctive clinical and histological features of Waldenstrm’s macroglobulinemia and splenic marginal zone lymphoma[J]. Clin Lymphoma Myeloma Leuk,2011,11(1):103-105.

[16] DU XF,MA ZP,LIN GS,et al. CT diagnosis and differentiation of nodular/mass-type hepatic lymphoma[J]. J Clin Hepatol,2017,33(8):1492-1496.(in Chinese)杜晓峰，马周鹏，林观生，等．6例肝脏结节/肿块型淋巴瘤患者的CT诊断及鉴别[J]．临床肝胆病杂志，2017,33(8):1492-1496.

[17] TSIMBERIDOU AM,CATOVSKY D,SCHLETTE E,et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone[J]. Cancer,2006,107(1):125-135.

[18] STARR AG,CAIMI PF,FU PF,et al. Splenic marginal zone lymphoma:Excellent outcomes in 64 patients treated in the rituximab era[J]. Hematology,2017,22(7):405-411.

[19] ELSE M,MARN-NIEBLA A,de la CRUZ F,et al. Rituximab,used alone or in combination,is superior to other treatment modalities in splenic marginal zone lymphoma[J]. Br J Haematol,2012,159(3):322-328.

[20] KOOT AW,VISSCHER AP,HUITS RM. Remission of splenic marginal zone lymphoma in a patient treated for hepatitis B:A case of HBV-associated lymphoma[J]. Acta Clin Belg,2015,70(4):301-303.

[21] KALPADAKIS C,PANGALIS GA,DIMITRIADOU E,et al. Mutation analysis of IgVH genes in splenic marginal zone lymphomas:Correlation with clinical characteristics and outcome[J].Anticancer Res,2009,29(5):1811-1816.

施引文献

资源附件(0)

访问统计